Emergent BioSolutions Q2 revenue $140.9M, beats guidance; raises FY profitability outlook

Emergent BioSolutions Inc.

2025-Q2 EPS reported $0.99 revenue$363,100,000

Q2 revenue $140.9M (above Q2 guidance by $21M); net loss improved to $12.0M from $283.1M loss a year ago.
Adjusted EBITDA swung to $28.5M from ($10.1M) loss; adjusted gross margin expanded to 49% from 26%.
Naloxone revenue down 44% to $67.5M; Smallpox MCM up 127% to $40.6M; Anthrax MCM down 70%.
Raised FY2025 adjusted EBITDA guidance to $175-$200M (prev. $150-$200M); adjusted gross margin 50-52%.
Secured $65M multi-year NARCAN contract with Ontario Ministry of Health and $114.3M in contract modifications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.